Cargando…

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?

We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial T(H)1 anticancer immune responses while suppressing the un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swarbrick, Alexander, Junankar, Simon R, Batten, Marcel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782520/ https://www.ncbi.nlm.nih.gov/pubmed/24083081 http://dx.doi.org/10.4161/onci.25409

Ejemplares similares

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

MAGE-A3-specific anticancer immunotherapy in the clinical practice
por: Brichard, Vincent G, et al.
Publicado: (2013)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy
por: Wimmers, Florian, et al.
Publicado: (2014)

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
por: Hailemichael, Yared, et al.
Publicado: (2013)

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
por: Shirwan, Haval, et al.
Publicado: (2013)

Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
por: Nelson, Peter J, et al.
Publicado: (2013)

A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy
por: McLellan, Alexander D
Publicado: (2014)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15
por: Müller, Dafne
Publicado: (2012)

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
por: Lazear, Eric, et al.
Publicado: (2017)

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma
por: Messaoudene, Meriem, et al.
Publicado: (2014)

Modulating CD27 signaling to treat cancer
por: Riether, Carsten, et al.
Publicado: (2012)

Cellular senescence enhances adaptive anticancer immunosurveillance
por: Marin, Ines, et al.
Publicado: (2022)

A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)

Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia
por: Fernandez Botana, Iria, et al.
Publicado: (2023)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Zoledronate-pulsed dendritic cell-based anticancer vaccines
por: Kamigaki, Takashi, et al.
Publicado: (2013)

Parvoviruses-tools to fine-tune anticancer immune responses
por: Grekova, Svitlana P., et al.
Publicado: (2012)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Shock block for improved immunotherapy
por: Rao, Aparna, et al.
Publicado: (2012)

ATM activation mediates anticancer immunosurveillance by natural killer and T cells
por: Tang, Melissa LF, et al.
Publicado: (2013)

Boosting anticancer vaccines: Too much of a good thing?
por: Ricupito, Alessia, et al.
Publicado: (2013)

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy
por: Ma, Yuting, et al.
Publicado: (2014)

An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
por: Senovilla, Laura, et al.
Publicado: (2013)

Modulating gut immunity and neoplasia with oral cytokine adjuvants
por: Ozbilge, Hatice, et al.
Publicado: (2015)

Interleukin-27 Signaling Promotes Immunity against Endogenously Arising Murine Tumors
por: Natividad, Karlo D. T., et al.
Publicado: (2013)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Personalizing immunotherapy: Balancing predictability and precision
por: Agur, Zvia, et al.
Publicado: (2012)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Empowering scFv with effector cell functions for improved anticancer therapeutics
por: Zhang, Hongtao
Publicado: (2013)

Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses
por: Wachowska, Malgorzata, et al.
Publicado: (2014)

Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
por: Balachandran, Riju S., et al.
Publicado: (2017)

NKT cell adjuvants in therapeutic vaccines against hematological cancers
por: Mattarollo, Stephen R., et al.
Publicado: (2013)

Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
por: Michaud, Mickaël, et al.
Publicado: (2012)

Humanizing mice for the identification of novel anticancer lipids targeting iNKT cells
por: Wen, Xiangshu, et al.
Publicado: (2013)

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
por: Binder, David C, et al.
Publicado: (2013)

Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects
por: Kepp, Oliver, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1t30epr0vsr1trhv6b4uj9fo97